Site search

Clear filter
2831 results for '' found
An open-label, multi-center, phase 1/2 study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with Relapsing Multiple Sclerosis with breakthrough disease activity durin
An open-label, multi-center, phase 1/2 study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with Relapsing Multiple Sclerosis with breakthrough disease activity durin
/
A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple Sys
A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple Sys
/
A phase 2 study to evaluate the efficacy and safety of ianalumab in patients with primary immune thrombocytopenia (ITP) previously treated with at least two lines of therapy (NCT05885555)
A phase 2 study to evaluate the efficacy and safety of ianalumab in patients with primary immune thrombocytopenia (ITP) previously treated with at least two lines of therapy (NCT05885555)
/
A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of
A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of
/
A phase Ib, multi-center, open-label dose escalation and expansion platform study of VAY736 as single agent and in combination with select antineoplastic agents in patients with non-Hodgkin Lymph
A phase Ib, multi-center, open-label dose escalation and expansion platform study of VAY736 as single agent and in combination with select antineoplastic agents in patients with non-Hodgkin Lymph
/
A phase 3, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1) (NCT05653349)
A phase 3, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1) (NCT05653349)
/
The role of CT Angiography as a suitable alternative to Invasive Coronary Angiography in detecting Left Main Restenosis (Trial Not Registered)
The role of CT Angiography as a suitable alternative to Invasive Coronary Angiography in detecting Left Main Restenosis (Trial Not Registered)
/
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous inj
/
A Phase 1, Open-label, Multiple Ascending Dose Basket Study to Evaluate the Safety and Activity of DR-0201 in Patients with Select Autoimmune Rheumatic Diseases (NCT06647069)
/
An Open label study to evaluate the long term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema (NCT04739059)
An Open label study to evaluate the long term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema (NCT04739059)
/
43 44 45 46 47